Introduction: Human mammaglobin is considered to be one of the most significant
Introduction
Breast carcinoma (BC) is the leading cause of cancer death in the USA with over 230,000 estimated new cases in 2014 and 40,000 estimated deaths (1) . Despite the achieved advance in the treatment of breast carcinoma by the applications of numerous hormonal, genetic and molecular markers (estrogen receptor (ER), progesteron receptor (PR), HER2, Ki67, etc.), high rates of mortality and morbidity are obvious related to this disease, so further study in this field is necessary with the aim of finding new markers as predictors of disease aggressiveness (2) (3) (4) . Breast cancer was classified into invasive ductal carcinoma (over 80% of total BC), invasive lobular carcinoma (10% of total BC) and other BC histological types that are not so common (10% of total BC) according to pathohistological features (5) . Improvement of medical achievements led to individualisation of therapy, i.e. selection of treatment tailored to individual patients (6) .
One of the specific breast cancer markers is the uteroglobin protein called human mammaglobin. This protein is detected both in normal breast tissue and in breast cancer.
Detected blood levels are increased in cancer and have prognostic significance (7, 8) .
Human mamaglobin was first detected in 1994 by Watson and Fleming using PCR method (9) . In addition to breast tissue, this uteroglobin protein occurs in two subtypes B1 and B2 that are detected in ovarian carcinoma (10) . In the literature, other names for human mamaglobin are also used: MAM, UGB3, SCGB2A1, MMG, MGB (11) . It has been an important predictor for bone metastases in breast cancer (12) . mRNA expression of mamaglobin may be multiplied in breast cancer versus non-malignant breast tissue (13) .
The overexpression of mammaglobin is probably caused by complex mechanism on the level of transcription (14) .
Span PN et al. demonstrated that mRNA expression of Mammaglobin A could be used for individualization of postoperative adjuvant treatment planning (15) . Human mamaglobin (hMAG) was also used to distinguish different breast carcinoma subtypes (16) . Human mamaglobin is positively expressed in 80% of the intraductal carcinoma and 90% of invasive ductal carcinoma (17) . The expression of human mammaglobin is in correlation with a high grade of breast cancer (18) .
There is no consensus in the literature on the association of human mamaglobin levels and the prognosis of the course of the disease (19) . Nunez-Villar et al. showed a correlation of human mamaglobin with less aggressive forms of the disease (20) . Many efforts have been made to detect mRNA mammaglobin in lymph nodes, blood and bone marrow in patients with breast carcinoma. The peculiarity of hMAG lies in its almost sole existence in mammary tissue and mammary carcinoma. In addition, the heightened expression in carcinomas and its association with tumour grades renders it an excellent marker for diagnosis and prognosis (21) .
BC early detection screening and other detection methods are still being studied. It is reported that expression of hMAG is mostly related to breast carcinoma tissue, and hMAG is defined as one of the first relatively mammary-specific markers (13) . There are many studies in literature that are related to mammaglobin level of the peripheral blood in BC patients, while there are not so many studies describing mammagilobin level in cancer tissue; studies concerning mammaglobin level of peritumoral tissue are really rare (22) (23) (24) .
Methods
This study presents a clinical observational cohort study along with an experimental study based on human origin material in vitro. The experimental research was carried out in 
Chemicals and reagents
Phosphate-buffered saline -PBS was provided by Gibco, the USA; chloroform, ethanol and isopropanol were provided by Serva Company, Germany. Human Mammaglobin-A ELISA kit and monoclonal antibody Anti-Human Antibody by My BioSource, inc. San Diego, CA, the USA.
QuantiTect Reverse Transcription Kit and PCR Kit (Sensiscript Reverse Transcriptase Kit -RT) were provided by Qiagen, Hilden, Germany. The PCR water and TRIzol were provided by Ambion, the USA. Gene expression Kit KapaSYBR® Green PCR Master Mix was provided by KAPA Biosystems, Boston, the USA. PCR primers were provided by Eurofins Genomics, Ebersberg.
Criteria for involving the patients in the study
with diagnosed early breast carcinoma. All the patients were examined by the Tumor board meeting of Clinical Centre Kragujevac, and then subjected to the appropriate surgical intervention. After the examination that had been carried out by the Tumor board meeting, tissue samples were taken willingly from patients and approvad of the Ethics Committee Clinical Centre of Kragujevac (no. 01-4990). All patients were given written information about the study details. During the surgeries carried out in General and Thoracic Surgery Clinic in Kragujevac, breast carcinoma (n=64) specimens and peritumoral tissue (n=64) specimens were collected. The carcinoma tissue samples appeared to be different in size depending on carcinoma size, and the peritumoral macroscopic unchanged tissue samples were taken to 3 cm from macroscopic carcinoma margin depending on the size of the excised breast tissue. All specimes were pathohistologically examined and verified by 
Tissue sample preparation
The sample was measured and homogenized on ice. Samples were homogenized in 500 μl cold lysis buffer for 0,01g of sample. IKA Homogeniser IKA®-Werke GmbH & Co. KG, Germany and Ultrasonic homogenizers Sonopuls, Bandelin electronic GmbH & Co. KG, Germany were used. Lysis buffer contained 31.25 mM Triss-HCl pH 6.8, 2% SDS, 10% glycerol and dH2O was added up to 100 ml. Аfter centrifuga-tion at 10 000 RPM at 4 °C, 10 min., supernatant was isolated and it presented the cell lysate. In this way the proteins from carcinoma and peritumoral tissue were isolated. The Lowry method was used to determine protein concentrations (27) .
Determining human mammaglobin-A concentration in carcinoma tissue
The human mammaglobin-A levels in carcinoma tissue were quantified using Human Mammaglobin-A ELISA kit and monoclonal antibody Anti-Human Antibody (My BioSource, inc. San Diego, CA, the USA) according to manufacturer's instructions.
Relative expression of mRNA mammaglobin gene
Total RNA from the carcinoma and peritumoral tissue was isolated using the phenolchloroform method by Chomezinski and Sacchi (28) . Concentrations and purity of RNA 
To calculate the expression of a target gene in relation to a reference gene, we used 2 -ΔCT method (30) .
Statistical analysis
All data are presented as the mean±SEM (standard error of the mean). The normality of distribution was tested by Kolmogorov-Smirnov test. The two-tailed Student's t-test, ANOVA test or nonparametric Mann-Whitney rank-sum test were used depending on the normality of distribution. Also, Chi-square test used for categorical variables.
A binary logistic regression model was used to evaluate prediction between two variables.
A receiver operating characteristic (ROC) curve analysis was employed to assess the diagnostic capabilities of the variables for prediction of distant metastasis. The results were considered significantly different when p<0.05. The data were analyzed using SPSS version 20, statistical package.
Results

Clinical and pathological characteristics of breast cancer (BC) patients
The levels of mammaglobin in carcinoma tissue and peritumoral tissue were observed and their prognostic value was analysed. Correlation between mammaglobin level in carcinoma tissue and peritumoral tissue and certain clinical pathological characteristics was also the object of the study. Clinical and pathological characteristics of the patients are described in 
Analysis of Mammaglobin A gene expression in carcinoma and peritumoral tissue in breast carcinoma patients (Figura 3 and 4)
Relative expression of Mamaglobin A is statistically significantly higher in carcinoma than in peritumoral tissue, regardless of the histological type of tumor, age of the patient, hormone or HER status ( Figure 3 ).
Relative expression of Mamaglobin A is statistically significantly higher in carcinoma than in peritumoral tissue, regardless of tumor size, number of affected lymph nodes, number of metastases and tumor grade ( Figure 4 ).
Prognostic significance of Mammaglobin A concentration in carcinoma and peritumoral tissue in breast carcinoma patients
As shown in Figure 5 , mammaglobin concentration in peritumoral tissue has a propensity for distant metastasis (binary logistic regression, p=0.024). Mammaglobin borderline value in carcinoma tissue is 0.67ng/ml for sensitivity 0.58 and specificity 0.59.
Mammaglobin concentration in carcinoma tissue has a propensity for distant metastasis (binary logistic regression, p=0.025). Mammaglobin borderline value in carcinoma tissue is 0.578ng/ml for sensitivity 0.67 and specificity 0.65 ( Figure 6 ).
Prognostic significance of Mammaglobin A gene expression in peritumoral and carcinoma tissue in breast carcinoma patients
As indicated in Figure 7 , mammaglobine gene expression in peritumoral tissue has no significant influence on occurance of distant metastasis (binary logistic regression, p=0.307).
Mammaglobin gene expression in carcinoma tissue identified by PCR method has a propensity for distant metastasis (binary logistic regression, p=0.043) (Figure 8 ).
Mammaglobin gene expression borderline value in carcinoma tissue is 1.003 for sensitivity 0.73 and specificity 0.76.
Discussion
Examination of hMGA mRNA levels of patients‗ peripheral blood results in 38, 2% sensitivity, 100% specificity, 100% positive prognostic value (PPV) and 61, 8% negative prognostic value (NPV) (31). There have been many studies describing mammaglobine level in patients' serum but not so many studies related to the mammaglobine level in carcinoma tissue; studies examining mammaglobin level in peritumoral tissue are very rare.
The peritumoral tissue is a relatively new research topic, and recent studies have presented its important role in breast cancer formation and development (32) . One of the studies that investigated mammaglobin levels in peritumoral, as well as tumoral tissue in breast cancer patient is the study of Zafracas et al. They found that mammaglobin was abundantly expressed in bouth malignant and normal breast tissues (11) . Our goal was analysis of gene and protein expression of mammaglobin in carcinoma tissue and peritumoral tissue. We also managed to dertermine specific values of these parameters in carcinoma tissue and peritumoral tissue that appeared to be of highly prognostic value.
The goal of modern oncology is personalized therapy, which presents the optimal method for a patient (33) . This study contributes to personalized therapy researches, dealing with analysis of potential correlation between mammaglobin expression in carcinoma tissue and peritumoral tissue and certain clinical pathological characteristics that are specific for each patient. We also managed to define specific values of mammaglobin levels (cut-off values) in carcinoma tissue and peritumoral tissue, having statistically proved prognostic values related to some of the most important prognostic parameters (e.g. distant and lymph nodes metastasis) for the outcome (34).
According to studied data, serum concentrations of mammaglobine were 0,07 -9,6 ng/ml compared to 0 -0,07 ng/ml of the control group (35 the test considered to be positive when values of mammaglobine were higher tan the given ones (36). In our study ROC curve showed that mammaglobin concentration value in peritumoral tissue can be used as a prognostic factor of distant metastasis (AUC= 0.693, p=0.027). Also, ROC curve showed that mammaglobin concentration value in carcinoma tissue can be used as a prognostic factor of distant metastasis (AUC= 0.698, p=0.019).
However, Bernstein JL rt al. claim that patients at stages I -III had mammaglobin values of 0,9 -1,4 ng/ml, and at stage IV the value 2,3 ng/ml. There was a strong positive correlation between mammaglobine values and carcinoma size; patients with a tumor of large diameter had higher serum concentrations of mammaglobin (37) . Our results match these data. There was an increased level of mammaglobin in carcinoma tissue and peritumoral tissue in patients with a larger breast tumor. As for the serum concentrations, results of our study showed concentrations of 2,6 ng/ml at stage Т1 up to those of 3,8 ng/ml at stage Т3. Values in peritumoral tissue were in significantly lower than those in carcinoma tissue-2,4 ng/ml at Т1 up to 3,6 ng/ml at Т3. We did not find similar studies while searching the available data bases so it was imposible to compare the results. To our knowledge, this is the first study of this kind that dealt with determining of mammaglobin tissue concentration.
Our results showed that there is a gradual increase of mammaglobin protein expression in carcinoma tissue and peritumoral tissue with higher possibility of lymphatic metastasis. For peritumoral tissue the values were at range 2,3 ng/ml -3,7 ng/ml, and for carcinoma tissue 2,6 ng/ml-3,8 ng/ml concerning N0 and N2 disease stages, respectively. Mean value of serum concentration of mammaglobin in patients with metastatic breast carcinoma was 9,38 ng/ml (7,9 ng/ml in the control group). Sensitivity was 68% and specificity 88,8%. Slight differences may appear because of different antibodies that were used in various studies (36) . Our results showed that mean value of mammaglobine determined by protein expression in patients with metastatic disease was 2,4 ng/ml -3,75 ng/ml in peritumoral, and 2,55 ng/ml -3,8 ng/ml in carcinoma tissue. Determining protein expression with ELISA test shows prognostic value related to distant metastasis in BC patients. Further, we defined specific cut-off values of mammaglobin concentration which indicate distant metastasis occurrence risks. This value was 0,6704221 ng/ml in peritumoral tissue, and 0,5784426 ng/ml in carcinoma tissue. We did not find similar studies while searching the available data bases so it was imposible to compare the results.
As for the tumor grade, our study showed that increased mammaglobin protein We did not show age dependance in mammaglobin expression, since the results were like those of other studies (38) . We defined specific values of mammaglobin concentration in carcinoma tissue and peritumoral tissue, and we showed that there were patients who were potentially at risk of disease development. They were suggested an adjuvant cancer treatment. Protein expression value was 0,6704221 ng/ml in peritumoral tissue, and 0,5784426 ng/ml in carcinoma tissue (ELISA test).
We also dealt with mammaglobin gene expression in carcinoma tissue and Gene expression of mammaglobin was slightly increased in carcinoma tissue of patients with metastasis. In peritumoral tissue it had values of 0,3 at М0 up to 0,5 at М1, and in carcinoma tissue 2,0 at М0 up to 5,5 at М1. 12% of cases M status was not defined so these patients were excluded from the study.
ROC curve shows that the value of mammaglobin gene expression in peritumoral
tissue cannot be used as a prognostic factor of distant metastasis (AUC= 0.553, p=0.546).
ROC curve shows that the value of mammaglobin gene expression in carcinoma tissue can be used as a prognostic factor of distant metastasis (AUC=0.838, p<0.01).
The study by Span et al. showed that increased gene expression was independently associated with longer non-relapse period. This was particularly evident in patients taking
Тamoxifen, indicating relation to hormonal status of tumor. Therefore, mammaglobin gene expression is considered to be a good prognostic marker (15) . There are some authors, nevertheless, stating that there was not a statistically significant correlation between gene expression level and hormonal status (48, 49 
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